These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24647159)

  • 1. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organizational effectiveness: a key to R&D productivity.
    Tollman P; Panier V; Dosik D; Biondi P; Cuss F
    Nat Rev Drug Discov; 2016 Jul; 15(7):441-2. PubMed ID: 27312725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can emerging drug classes improve R&D productivity?
    Meier C; Cairns-Smith S; Schulze U
    Drug Discov Today; 2013 Jul; 18(13-14):607-9. PubMed ID: 23702084
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 7. Combating the cons of consolidation.
    Nat Rev Drug Discov; 2009 Mar; 8(3):177. PubMed ID: 19263592
    [No Abstract]   [Full Text] [Related]  

  • 8. Do large mergers increase or decrease the productivity of pharmaceutical R&D?
    Ringel MS; Choy MK
    Drug Discov Today; 2017 Dec; 22(12):1749-1753. PubMed ID: 28646641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An assessment of R&D productivity in the pharmaceutical industry.
    Dimitri N
    Trends Pharmacol Sci; 2011 Dec; 32(12):683-5. PubMed ID: 22030299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precompetitive consortia in biomedicine--how are we doing?
    Mittleman B; Neil G; Cutcher-Gershenfeld J
    Nat Biotechnol; 2013 Nov; 31(11):979-85. PubMed ID: 24213770
    [No Abstract]   [Full Text] [Related]  

  • 11. Large drug firms narrow their therapeutic interests.
    Mullard A
    Lancet; 2014 May; 383(9932):1873. PubMed ID: 24892171
    [No Abstract]   [Full Text] [Related]  

  • 12. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. David Haslam. Interview by Asher Mullard.
    Haslam D
    Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
    [No Abstract]   [Full Text] [Related]  

  • 14. Torching the Haystack: modelling fast-fail strategies in drug development.
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2013 Apr; 18(7-8):331-6. PubMed ID: 23246516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Driving clinical study efficiency by using a productivity breakdown model: comparative evaluation of a global clinical study and a similar Japanese study.
    Takahashi K; Sengoku S; Kimura H
    J Clin Pharm Ther; 2011 Feb; 36(1):87-98. PubMed ID: 21198723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of mergers on pharmaceutical R&D.
    LaMattina JL
    Nat Rev Drug Discov; 2011 Aug; 10(8):559-60. PubMed ID: 21804580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Open innovation: public-private partnerships in pharmaceutical R&D].
    Uchibayashi N
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):32-8. PubMed ID: 23842226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.